Background. Pneumococcal conjugate vaccine (PCV) is now recommended for use in adults in the United States. Because vaccination of children with PCVs protects adults from the targeted serotypes, local variations in PCV uptake among children could influence disease patterns in adults.
Pneumococcal conjugate vaccines (PCVs) have been used in children in the United States for over a decade. Introduction of the original conjugate vaccine (7-valent PCV [PCV7]) was associated with rapid declines in invasive pneumococcal disease (IPD) caused by the PCV7-targeted serotypes among both children (who received the vaccine) and adults (who did not receive the vaccine) [1] [2] [3] [4] .
There are still important questions about how to best protect adults from pneumococcal disease. Recently, the Advisory Committee on Immunization Practices recommended routine use of PCV13 among adults aged ≥65 years in the United States [5] . However, because adults are indirectly protected when children receive PCVs, the fraction of IPD cases in adults that can be prevented declines over time, and it is not clear whether direct immunization of adults with the same vaccine would be effective [6, 7] .
Little is known about how vaccine uptake rates (and the use of booster doses), transmission intensity, and serotype distributions vary between communities. Variations in these factors could result in geographic pockets that have a higher or lower fraction of IPD cases caused by vaccine-targeted serotypes. This, in turn, would influence the impact of direct immunization of adults with PCVs.
We tested the hypothesis that in the years following vaccine introduction, PCV7-targeted serotypes caused a disproportionate fraction of IPD cases among adults living in communities with a lower socioeconomic status (SES) or lower uptake of PCV7 among children. We evaluated this hypothesis by using statewide data from Connecticut on the incidence of IPD among children and adults and data on PCV7 uptake among children.
METHODS

Data Sources
Data on invasive pneumococcal cases were collected from the Active Bacterial Core surveillance system for Connecticut during 1998-2009 [4] . For each case, we had data on the month and year of sampling, the serotype, and the age group (<5 years, 5-17 years, 18-39 years, 40-64 years, and >65 years). Data from the post-PCV13 period (after 2010-2013) were not included because the vaccine-uptake database does not distinguish PCV7 doses from PCV13 doses.
Data on PCV7 uptake, by ZIP code, were obtained from the Connecticut Immunization Registry and Tracking System (CIRTS). CIRTS is a mandatory, opt-out registry used to keep permanent records of the vaccination of children up through the age of 2 years for most children. The registry captured approximately 84% of children (176 923) born in Connecticut between 2001 and 2005 . Approximately 10% of families opt out of the registry, and the other missing data constitute loss to follow-up (eg, due to relocation out of state) or incomplete records. The data were aggregated by birth cohort and ZIP code, and we obtained the total number of children in the registry in each strata and the number of children who received 3 or 4 doses of PCV7. To estimate the total coverage of PCV7 in each month and ZIP code among children 12-59 months of age, we used a cohort approach similar to that used by Nuorti et al [8] . We assumed that the birth rate was constant over the year and that all children who received 3 or 4 doses of vaccine by 2 years of age were vaccinated according to schedule. Because we wanted to focus on the importance of variations in vaccine uptake between ZIP codes, we mean centered these vaccine uptake variables: for each date, we subtracted the mean uptake of ≥3 or ≥4 doses of PCV7 for Connecticut from the observed uptake of ≥3 or ≥4 doses in each ZIP code. These new mean-centered variables are centered around 0 at each date (Supplementary Figure 1) .
To quantify the additional benefit of 4 doses of PCV7, compared with 3 doses, we subtracted the ≥4-dose uptake variable from the ≥3-dose uptake variable and then subtracted the mean at each date from this variable. This variable indicates whether the percentage of children in a ZIP code who received 3 doses but did not receive a fourth dose differed from the state average. We did not have data available on age of vaccination, but we assumed that most of the children who received only 3 doses received 3 primary doses of PCV7 but did not receive a booster (effectively a 3 + 0 dose schedule). CIRTS does not indicate the age of vaccination and does not distinguish booster doses from doses in the primary series.
Demographic data for each ZIP code tabulation area were obtained from the US Census Bureau for each ZIP code in Connecticut. We collected information on SES indicators, such as the percentage of the population that was black, white, or Hispanic; income per capita; population density; and population size in each ZIP code.
The Human Investigation Committees at Yale School of Medicine and the Connecticut Department of Public Health approved this study. Certain data used in this study were obtained from the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of this data.
Estimating the Rate of Decline of Vaccine Serotypes
We estimated the overall rate of decline of vaccine serotypes in each age group using a logistic regression where the outcome variable was the proportion of cases of IPD in a given month caused by a vaccine serotype. The typical approach would be to fit a trend line to these data, to estimate this decline over time. However, there is uncertainty about exactly when this decline should begin, and the timing of the decline might vary between age groups. To capture the uncertainty, we used a linear spline, where the location of the spline knot (the change point) was unknown. This provides a robust estimate for the rate of decline and an estimate for when the decline begins in each age group. For more details, see the Supplementary Methods.
Factors Associated With PCV7 Uptake in Children
To evaluate factors associated with variations in vaccine uptake, we fit a logistic regression model. The outcome variable was the proportion of children in the CIRTS registry within a given ZIP code that received ≥3 or ≥4 doses of PCV7. The covariates were ZIP code-level SES factors, including proportion of the population in the ZIP code that was black or Hispanic, the proportion aged 5 years, logarithm of income per capita, and logarithm of population density (overall and for children aged <5 years). This particular analysis used vaccine uptake data from a single date (1 January 2006), with the assumption that the relative differences in uptake between ZIP codes was consistent over time. This date was chosen because the vaccine program had matured by this point (ie, the entire cohort of children aged <5 years should have been vaccinated according to schedule). A significant value (P < .05) for the SES variable was taken as evidence that vaccine uptake differed by SES characteristic in a ZIP code.
Descriptive Analysis for Relationship Between Vaccine Uptake and Serotype Distribution
To evaluate the link between vaccine uptake and the proportion of IPD cases caused by a PCV7 serotype among adults aged ≥40 years, each ZIP code in each year was assigned to a quintile based on the uptake of 4 doses of PCV7 in that ZIP code. We then compared the average uptake of PCV7 for each of these quintiles in each year and the observed proportion of IPD cases caused by PCV7 serotypes in each of these quintiles.
Factors Associated With Variations in Proportion PCV7
To determine whether PCV7 uptake or SES factors were associated with variations in the serotype distribution among IPD cases, we fit a logistic regression. The outcome variable was the proportion of IPD cases at a given date and ZIP code that was caused by a PCV7 serotype. For this analysis, we focused only on adults ≥40 years of age. Based on the results of the change point analyses, all models included a linear spline (with a knot in June 2001) to capture the average decline in PCV7 serotypes across all ZIP codes. The ZIP code-level covariates were uptake of 3 doses of the vaccine (mean centered for each date), uptake of 4 doses of the vaccine (mean centered for each date), the difference between uptake of 3 and 4 doses of the vaccine (mean centered for each date), proportion of the population that was black or Hispanic, the proportion of the population aged <5 years, logarithm of population density (overall, aged <5 years, and aged >65 years), and logarithm of income per capita. We fit models with different combinations of covariates and selected the best model based on the Akaike information criterion (AIC). All of the tested models and their associated AIC scores are listed in Supplementary Table 1 .
To evaluate the fit of the best model, we separated the ZIP codes into 5 quintiles in each year based on the predicted odds that an IPD case was caused by a PCV7 serotype. Within each quintile and each year, we estimated the observed proportion of disease cases caused by PCV7 serotypes and the mean proportion predicted by the model. The observed and expected values of these quintiles should be similar in all years if the model fits well.
All models were fit using PROC GENMOD (SAS, version 9.3; Cary, North Carolina).
RESULTS
Characteristics of IPD and Vaccine Data
From 1998 to 2009, there were 5838 cases of IPD captured in our database. Of these cases, 709 occurred among <5-year-old children, 226 among 5-17-year-old individuals, 581 among 18-39-year-old individuals, 1947 among 40-64-year-old individuals, and 2375 among those aged ≥65 years. Across all 12 years of data collection, 3525 cases were caused by non-PCV7 serotypes, while 2313 cases were caused by PCV7 serotypes.
By 2009, 94.7% of the children in the vaccine registry were vaccinated with at least 3 doses of PCV7, and 88.4% were vaccinated with 4 doses of PCV7. Our numbers were slightly lower than those from the National Immunization Survey, which estimated that 98.8% of children had ≥3 doses of PCV7 vaccine in 2009 [9] .
Changes in the Proportion of Disease Cases Caused by PCV7 Serotypes
After PCV7 was introduced in 2000, the proportion of IPD cases caused by the 7 targeted serotypes declined in all age groups ( Figure 1A ). This decline was evident among children <5 years in early 2000, while the decline was delayed by approximately 17 months among adults aged 40-64 years and ≥65 years ( Figure 1B) . The decline among children aged 5-17 years was further delayed, until late 2002. The decline of the PCV7 serotypes among the children aged <5 years was significantly more rapid than among the adults. The decline among children aged <5 years was −62.7% per year (95% confidence interval [CI], −68.8 to −55.4%), compared with −36.2% (95% CI, −40.3 to −32.0%) and −37.0% (95% CI
Variations in PCV7 Uptake
Uptake of ≥3 and ≥4 doses of PCV7 varied substantially between ZIP codes ( Figure 2B ). In univariable analyses, ZIP codes with lower uptake of ≥3 or ≥4 doses of PCV7 were significantly more likely to have a higher percentage of the population that was black or Hispanic and a higher percentage of the population aged <5 years, and they tended to have a higher population density overall and population density of children <5 years of age (Table 1 ). Figure 1 . Decline in 7-valent pneumococcal conjugate vaccine (PCV7) serotypes in Connecticut over time. A, The proportion of invasive pneumococcal disease cases caused by PCV7 serotypes in each month and year, by age group, in 1998-2009. B, The probability that the PCV7-associated decline begins in any given month. These distributions can be compared to estimate how long it takes the indirect effect to reach unvaccinated age groups.
Factors Associated With Higher Proportions of PCV7 Serotypes in Adults
ZIP codes with lower-than-average PCV7 uptake (≥3 or ≥4 doses) at a given date tended to have a higher proportion of IPD cases caused by PCV7 serotypes ( Figure 3 and Table 2 ). The ≥3 and ≥4 categories likely correspond to 3 + 0 and 3 + 1 dosing schedules. Variables associated with lower SES status (eg, population density) were not significantly associated with the serotype distribution ( Table 2 and Supplementary  Table 1) .
In the multivariable model with the best fit (Table 2) , a higher odds of having a case of IPD caused by a PCV7 serotype was associated with a higher-than-average percentage of children who did not receive the fourth dose after having received 3 doses. As the gap between 3 and 4 dose coverage increased by 10 percentage points, the odds of an IPD case being caused by a PCV7 serotype increased by 54.3% (95% CI, 20.2%-98.2%). There was a nonsignificant association between uptake of 3 doses of PCV7 and serotype distribution (Table 2) . Additionally, the 40-64-year-old age category had a −16.0% lower odds of an IPD PCV7 case, compared with the ≥65-year-old age category.
This model accurately captured variations in the proportion of IPD cases caused by PCV7 serotypes for all years (Figure 4) . Four years after vaccine introduction, the model predicted that 16%-25% of cases would be caused by PCV7 serotypes. By 2009, the model predicted that just 3%-5% of cases would be caused by PCV7 serotypes.
Several other models also fit the data well (ie, they had an AIC score within 2 points of the best model). All of these well-fitting models included age group, uptake of ≥3 doses of PCV7 (mean centered), and either uptake of ≥4 doses of PCV7 (mean centered) or the difference between ≥3 and ≥4 doses of PCV7 (mean centered). Population density (log transformed) was also included in several of the best models (Table 2 and Supplementary Table 1 ) but did not affect the estimates of the importance of vaccine uptake (Table 2) .
DISCUSSION
PCVs are now in use among children around the world, and many countries are considering whether adults should also receive the same vaccine. Adults receive strong indirect protection in settings with high uptake of PCVs among children. In our data, only a small fraction of IPD cases in adults were caused by PCV7 serotypes after a decade of vaccine use in children. In such settings, immunizing adults with the same vaccine as children might have minimal impact against IPD. Further information about the serotype distribution in noninvasive pneumococcal pneumonia would be needed to determine whether the vaccine would have an important impact on overall disease burden. Our analyses suggest that local variations in vaccine uptake among children might cause PCV-targeted serotypes to persist as causes of disease in adults when the uptake levels are not optimal. In locations where vaccine uptake is less complete, either due to vaccine refusals or deficiencies in the public health system, local variations in PCV uptake in children might influence the serotype distribution in adults and could influence costbenefit analyses evaluating the use of PCVs in adults.
Given the costs associated with PCVs, there is substantial interest in considering alternative dosing or reduced-dose schedules. Because much of the benefit derived from PCVs results from indirect protection [10] , it is important to consider how dosing schedules might influence such indirect effects. A systematic review of dosing schedules on carriage and disease [11, 12] suggested that a variety of dosing schedules can indirectly protect adults. The review suggested that, in the first year of life, ≥3 doses had a greater effect on the risk of colonization than 2 doses. There were not clear differences between dosing schedules on the magnitude of the indirect effect against IPD or pneumonia. A randomized controlled trial from the Netherlands demonstrated small differences in colonization with PCV7 serotypes between children receiving 2 + 0 and 2 + 1 dosing schedules. These differences were apparent at 12 and 18 months of age but disappeared by 24 months of age. If the younger children play a role in transmission, differences in colonization could be amplified when the vaccine is used in the community. In our vaccine data, we only know the total number of doses received by the age of 2 years, so we cannot determine whether a child who received only 3 doses effectively received a 2 + 1 or 3 + 0 dosing schedule. However, based on experience, we believe that most of these children would have received the 3 primary doses and not the booster dose (effectively a 3 + 0 schedule). Therefore, our results would support the notion that the booster dose of PCV might have an additional benefit beyond that provided with 3 doses of vaccine in indirectly protecting adults against IPD. Our study has the advantage of being able to examine the question of vaccine dosing in the context of a single study population over time. This type of analysis will need to be repeated in an independent setting to evaluate the potential impact of the booster dose on protecting adults from IPD and to consider the impact of booster doses on indirect protection when used in a 2 + 1 schedule or 3 + 1 schedule.
Uptake of PCVs in children in Connecticut has been high overall, with approximately 95% of children in the CIRTS registry having received at least 3 doses of PCV7. Uptake of 4 doses of PCV7 still lags behind in some ZIP codes in Connecticut. In particular, areas with lower socioeconomic indicators tended to have lower uptake of PCV7. Outreach to low-income communities may be needed to improve 4-dose vaccination rates in these areas.
The United States switched from using PCV7 to PCV13 in 2010. The relationship between PCV uptake in children and disease rates in adults may or may not translate to the post-PCV13 period. If PCV13 has a similar impact on pediatric carriage, we would expect to see a similar pattern. However, if PCV13 is ineffective in blocking transmission against certain serotypes, or if some serotypes can be transmitted exclusively among adults (without needing to be exposed to children), then we might not expect there to be a strong link between PCV13 uptake in children and serotype distribution in adults. Unfortunately, our vaccine uptake data do not allow us to explore this question because the CIRTS database did not distinguish between PCV7 and PCV13, so we cannot estimate ZIP code-level uptake of PCV13.
Our results have some limitations. This is an observational study with ecological data. As a result, associations between vaccine uptake and serotype distribution at the ZIP code level should be interpreted with caution. While we control for demographic characteristics in our multivariable model, we cannot exclude the possibility that other unmeasured confounders impact serotype distribution at the ZIP code level. For instance, it is possible that higher rates of comorbidities in some communities might increase the risk for developing vaccine-serotype disease. Our approach of analyzing the proportion of disease cases caused by vaccine serotypes, rather than incidence, partly controls for this issue by implicitly adjusting for differences in disease risk between communities. This assumes that the factors that lead to persistence of vaccine serotypes are the same factors that influence the risk for disease caused by nonvaccine serotypes. Not every child in Connecticut is present in the CIRTS immunizations registry. The vaccination status of approximately 15% of the children is unknown, so our vaccine uptake estimates may underestimate or overestimate the true coverage level in the ZIP codes. Additionally, the CIRTS registry primarily follows children through age 2 years, so if the fourth dose of PCV is delayed beyond age 2 years, it will not be captured in the registry. If some populations are more likely to delay the fourth dose, this could influence the interpretation of our results.
In conclusion, we have identified an association between local variations in PCV uptake among children and the distribution of serotypes causing disease among adults in the United States. This underscores the importance of maintaining high coverage of PCVs among the pediatric population for protecting individuals of all ages.
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